Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
J Dermatol
; 46(2): 124-130, 2019 Feb.
Article
in En
| MEDLINE
| ID: mdl-30585649
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Diseases, Vesiculobullous
/
Rituximab
/
Immunologic Factors
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
En
Journal:
J Dermatol
Year:
2019
Document type:
Article
Affiliation country:
Japan
Country of publication:
United kingdom